X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xiamen Amoytop Biotech Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Short-Term Debt
ÂĄ4.7B
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Short-Term Debt
ÂĄ173.1m
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Short-Term Debt
ÂĄ168.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Short-Term Debt
ÂĄ3.4B
CAGR 3-Years
23%
CAGR 5-Years
14%
CAGR 10-Years
46%
Imeik Technology Development Co Ltd
SZSE:300896
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Short-Term Debt?
Short-Term Debt
0 CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Short-Term Debt amounts to 0 CNY.

Back to Top